Rui Fang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rui Fang has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Huiping Luo
ENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China
6 shared publications - Chunsheng Wei
ENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China
5 shared publications Chao Xue
ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital Fudan University Shanghai China
3 shared publications- Chen Chen
Human Phenome Institute, Fudan University, Shanghai 201203, China
3 shared publications - Wei Chen
The University of Sydney
3 shared publications Xiufa Wu
ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital Fudan University Shanghai China
3 shared publications
Latest Publications
- 22 September 2026
- Published by Springer Nature in Phenomics
- Vol. 6 (5) , 784-787
Clinical and Upper Airway Microbial Signatures in Severe Obstructive Sleep Apnea: Association and Prediction
- 22 September 2026
- Published by Springer Nature in Phenomics
- Vol. 6 (5) , 784-787
Clinical and Upper Airway Microbial Signatures in Severe Obstructive Sleep Apnea: Association and Prediction
- 18 September 2026
- Published by Elsevier in Journal of Voice
Validation of FUDAN VOICE: Signal and Acoustic Feature Comparison with Computerized Speech Lab (CSL)
- 18 September 2026
- Published by Elsevier in Journal of Voice
Validation of FUDAN VOICE: Signal and Acoustic Feature Comparison with Computerized Speech Lab (CSL)
- 6 March 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Biomedical and Health Informatics
- Vol. PP (21682194) , 1-12
A 1D Snoring Waveform and 2D Composite Acoustic Feature Graph-Based Multi-Modal Fusion Network for Obstructive Sites Recognition
As a critical factor in diagnostic work-up and treatment decision-making process of sleep-related breathing disorders, accurate localization of obstructive sites in the upper airway is in dire need. Snoring, as a dynamic acoustic signal, carries informative information relating to the sites and degree of obstruction in the upper airway, offering a non-invasive, cost-effective solution for obstructive sites recognition. However, most of existing snoring-based methods for recognizing obstructive sites only involve limited information (either mainly concentrated on traditional acoustic characteristics or spectrogram features), which may omit dynamic pathological information. Moreover, existing methods proceed from either a one-dimensional (1D) signal or two-dimensional (2D) image perspective, where complementary information from the other modality may be overlooked. In this paper, a multi-modal framework, which combines 1D snoring waveform and 2D Composite Acoustic Feature Graph (CAF-Graph), is proposed. 1D snoring waveform perceives fine time structure and local patterns, aiming at learning high-level discriminative representations by neural networks. 2D CAF-Graph is dedicated to emphasizing dynamic spatio-temporal and physiological-acoustic characteristic of snoring, which concatenates acoustic features related to Prosodic, Formant, Spectral, and Cepstral characteristics. Further, a multi-modal fusion network (BMFNet) effectively integrates independent and interactive information between single-modal features, which offers a more comprehensive perspective. The recognition task was formulated as a three-class classification problem, including upper (snoring caused by upper-level obstruction), lower (snoring caused by lower-level obstruction), and silence (obstruction without snoring). The proposed method was validated on a clinical dataset collected in the ENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, where reached 81.2% Accuracy, 86.8% Weighted Average Precision, 81.2% Weighted Average Recall, and 82.3% Weighted Average F1-Score. Results exhibit the effectiveness of multi-modal feature representations for snoring, providing a novel insight for obstructive sites recognition tasks.
- 6 March 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Biomedical and Health Informatics
- Vol. PP (21682194) , 1-12
A 1D Snoring Waveform and 2D Composite Acoustic Feature Graph-Based Multi-Modal Fusion Network for Obstructive Sites Recognition
As a critical factor in diagnostic work-up and treatment decision-making process of sleep-related breathing disorders, accurate localization of obstructive sites in the upper airway is in dire need. Snoring, as a dynamic acoustic signal, carries informative information relating to the sites and degree of obstruction in the upper airway, offering a non-invasive, cost-effective solution for obstructive sites recognition. However, most of existing snoring-based methods for recognizing obstructive sites only involve limited information (either mainly concentrated on traditional acoustic characteristics or spectrogram features), which may omit dynamic pathological information. Moreover, existing methods proceed from either a one-dimensional (1D) signal or two-dimensional (2D) image perspective, where complementary information from the other modality may be overlooked. In this paper, a multi-modal framework, which combines 1D snoring waveform and 2D Composite Acoustic Feature Graph (CAF-Graph), is proposed. 1D snoring waveform perceives fine time structure and local patterns, aiming at learning high-level discriminative representations by neural networks. 2D CAF-Graph is dedicated to emphasizing dynamic spatio-temporal and physiological-acoustic characteristic of snoring, which concatenates acoustic features related to Prosodic, Formant, Spectral, and Cepstral characteristics. Further, a multi-modal fusion network (BMFNet) effectively integrates independent and interactive information between single-modal features, which offers a more comprehensive perspective. The recognition task was formulated as a three-class classification problem, including upper (snoring caused by upper-level obstruction), lower (snoring caused by lower-level obstruction), and silence (obstruction without snoring). The proposed method was validated on a clinical dataset collected in the ENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, where reached 81.2% Accuracy, 86.8% Weighted Average Precision, 81.2% Weighted Average Recall, and 82.3% Weighted Average F1-Score. Results exhibit the effectiveness of multi-modal feature representations for snoring, providing a novel insight for obstructive sites recognition tasks.
- Open Access
- 1 January 2026
- Published by China Engineering Science Press Co. Ltd.
Exhaled Nitric Oxide in Obstructive Sleep Apnea: Compartment-Specific Associations and Incremental Predictive Value
Background: Airway inflammation is implicated in obstructive sleep apnea (OSA), but nitric oxide signals from different respiratory compartments may provide distinct information. We examined compartment-specific exhaled nitric oxide (eNO) profiles and whether eNO improved OSA prediction beyond routine clinical and anthropometric characteristics. Methods: This prospective cross-sectional study included 965 participants who underwent polysomnography and measurement of fractional exhaled nitric oxide at 50 mL/s (FeNO50), alveolar nitric oxide concentration (CaNO), and fractional nasal nitric oxide at 10 mL/s (FnNO10). Base models were compared with FeNO50-augmented and complete-eNO-panel models using seven classification algorithms and repeated stratified nested cross-validation. Discrimination, calibration, class-specific performance, and clinical net benefit were evaluated for OSA and sleep-related hypoxemia.Results: Of the 965 participants, 798 had OSA and 167 did not. FeNO50 was higher in participants with OSA (median, 21.00 [interquartile range, 16.00–29.00] vs. 18.00 [13.00–23.00] ppb; p < 0.001). CaNO showed a modest between-group difference, whereas FnNO10 did not differ between groups. FeNO50 was elevated across OSA severity categories without a clear dose–response gradient. It was not correlated with apnea-hypopnea index (AHI) and showed only a very weak inverse correlation with nadir oxygen saturation, while remaining independently associated with OSA after multivariable adjustment. Adding FeNO50 resulted in small, nonsignificant changes in area under the receiver operating characteristic curve (ROC-AUC) for OSA (ΔAUC, −0.009 to 0.009) and hypoxemia (ΔAUC, −0.009 to 0.002). The complete eNO-panel models achieved ROC-AUCs of 0.769–0.839 for OSA and 0.788–0.820 for hypoxemia.Conclusions: FeNO50 captures an airway inflammatory phenotype associated with OSA but does not closely reflect polysomnographic severity. Its incremental predictive contribution beyond established clinical and anthropometric characteristics was limited, supporting its use as complementary phenotypic information rather than a stand-alone OSA screening test.
- 1 January 2026
- Published by China Engineering Science Press Co. Ltd.
Open AccessExhaled Nitric Oxide in Obstructive Sleep Apnea: Compartment-Specific Associations and Incremental Predictive Value
Background: Airway inflammation is implicated in obstructive sleep apnea (OSA), but nitric oxide signals from different respiratory compartments may provide distinct information. We examined compartment-specific exhaled nitric oxide (eNO) profiles and whether eNO improved OSA prediction beyond routine clinical and anthropometric characteristics. Methods: This prospective cross-sectional study included 965 participants who underwent polysomnography and measurement of fractional exhaled nitric oxide at 50 mL/s (FeNO50), alveolar nitric oxide concentration (CaNO), and fractional nasal nitric oxide at 10 mL/s (FnNO10). Base models were compared with FeNO50-augmented and complete-eNO-panel models using seven classification algorithms and repeated stratified nested cross-validation. Discrimination, calibration, class-specific performance, and clinical net benefit were evaluated for OSA and sleep-related hypoxemia.Results: Of the 965 participants, 798 had OSA and 167 did not. FeNO50 was higher in participants with OSA (median, 21.00 [interquartile range, 16.00–29.00] vs. 18.00 [13.00–23.00] ppb; p < 0.001). CaNO showed a modest between-group difference, whereas FnNO10 did not differ between groups. FeNO50 was elevated across OSA severity categories without a clear dose–response gradient. It was not correlated with apnea-hypopnea index (AHI) and showed only a very weak inverse correlation with nadir oxygen saturation, while remaining independently associated with OSA after multivariable adjustment. Adding FeNO50 resulted in small, nonsignificant changes in area under the receiver operating characteristic curve (ROC-AUC) for OSA (ΔAUC, −0.009 to 0.009) and hypoxemia (ΔAUC, −0.009 to 0.002). The complete eNO-panel models achieved ROC-AUCs of 0.769–0.839 for OSA and 0.788–0.820 for hypoxemia.Conclusions: FeNO50 captures an airway inflammatory phenotype associated with OSA but does not closely reflect polysomnographic severity. Its incremental predictive contribution beyond established clinical and anthropometric characteristics was limited, supporting its use as complementary phenotypic information rather than a stand-alone OSA screening test.
- 4 August 2025
- Published by Wiley in The Laryngoscope
- Vol. 136 (1) , 351-359
Pathological Grading Determines the Clinical Efficacy of Outpatient KTP Laser Treatment for Vocal Fold Leukoplakia
Objective: Vocal fold leukoplakia is commonly managed with outpatient potassium titanyl phosphate (KTP) laser therapy; however, limited data exist on the impact of different pathological grades on long‐term efficacy. This study retrospectively analyzed the treatment outcomes, identified prognostic factors, and provided insights to improve disease characterization and clinical management. Study Design: Retrospective study (2017–2024). Methods: Ninety two patients with vocal fold leukoplakia treated in Fudan Eye and ENT hospital (FD‐EENT) were included. The mean follow‐up period after the last treatment was 20.53 ± 17.32 months. Disease control was assessed by lesion regression using ImageJ analysis. Acoustic outcomes were evaluated using the Voice Handicap Index‐30 (VHI‐30), GRBAS scale, and other acoustic parameters. Results: Patients underwent a mean of 1.6 treatment sessions. Following the last treatment, the lesion regression rates were 90.1% for no dysplasia, 81.75% for mild dysplasia, and 86.83% for moderate dysplasia, compared to 51.0% for severe dysplasia and 32.9% for carcinoma in situ (CIS). Patients with pathological grades of severe dysplasia and CIS showed significantly poorer treatment outcomes than those with milder dysplasia (*** p = 0.0001). Conclusion: Outpatient KTP laser effectively controls disease progression in vocal fold leukoplakia, with efficacy linked to the degree of dysplasia. KTP laser is an effective treatment for milder pathological dysplasia, but its efficacy diminishes in more severe stages. The treatment should be carefully considered for patients with severe dysplasia and CIS, with close follow‐up, and biopsy should be performed to monitor malignant transformation and prevent delayed treatment. Level of Evidence: 4.
- 4 August 2025
- Published by Wiley in The Laryngoscope
- Vol. 136 (1) , 351-359
Pathological Grading Determines the Clinical Efficacy of Outpatient KTP Laser Treatment for Vocal Fold Leukoplakia
Objective: Vocal fold leukoplakia is commonly managed with outpatient potassium titanyl phosphate (KTP) laser therapy; however, limited data exist on the impact of different pathological grades on long‐term efficacy. This study retrospectively analyzed the treatment outcomes, identified prognostic factors, and provided insights to improve disease characterization and clinical management. Study Design: Retrospective study (2017–2024). Methods: Ninety two patients with vocal fold leukoplakia treated in Fudan Eye and ENT hospital (FD‐EENT) were included. The mean follow‐up period after the last treatment was 20.53 ± 17.32 months. Disease control was assessed by lesion regression using ImageJ analysis. Acoustic outcomes were evaluated using the Voice Handicap Index‐30 (VHI‐30), GRBAS scale, and other acoustic parameters. Results: Patients underwent a mean of 1.6 treatment sessions. Following the last treatment, the lesion regression rates were 90.1% for no dysplasia, 81.75% for mild dysplasia, and 86.83% for moderate dysplasia, compared to 51.0% for severe dysplasia and 32.9% for carcinoma in situ (CIS). Patients with pathological grades of severe dysplasia and CIS showed significantly poorer treatment outcomes than those with milder dysplasia (*** p = 0.0001). Conclusion: Outpatient KTP laser effectively controls disease progression in vocal fold leukoplakia, with efficacy linked to the degree of dysplasia. KTP laser is an effective treatment for milder pathological dysplasia, but its efficacy diminishes in more severe stages. The treatment should be carefully considered for patients with severe dysplasia and CIS, with close follow‐up, and biopsy should be performed to monitor malignant transformation and prevent delayed treatment. Level of Evidence: 4.
- 11 July 2024
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 56 (7) , 657-663
Combined CO2 Laser Vaporization and Bleomycin Injection to Treat Huge Adult Laryngeal Vascular Anomalies: Innovative Application of CO2 Laser in Otolaryngology
Objectives: The aim of this study was to assess the value of CO2 laser vaporization in treating huge adult laryngeal vascular anomalies (HALVAs) by combining it with bleomycin injection.Materials and Methods: This study retrospectively reviewed the records of 13 adult patients who underwent 18 different procedures. Methods to treat HALVAs include traditional bleomycin injection and CO2 laser vaporization combined with bleomycin injection between September 2009 and January 2023. Treatment results were evaluated by the grade of lumen constriction.Results: A total of five males and eight females, with an average age of 46.3 years (range, 22–66 years), were included in the study. The huge adult laryngeal vascular anomalies in our study were greater than 1633.71 mm3, and the long diameters of the bases were longer than 15 mm. Compared with the bleomycin injection‐only group, the results with the CO2 laser vaporization and bleomycin injection combined were better.Conclusions: Both bleomycin injection and CO2 laser vaporization are safe treatment methods. Their combination may produce better results for huge adult laryngeal vascular anomalies.
- 11 July 2024
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 56 (7) , 657-663
Combined CO2 Laser Vaporization and Bleomycin Injection to Treat Huge Adult Laryngeal Vascular Anomalies: Innovative Application of CO2 Laser in Otolaryngology
Objectives: The aim of this study was to assess the value of CO2 laser vaporization in treating huge adult laryngeal vascular anomalies (HALVAs) by combining it with bleomycin injection.Materials and Methods: This study retrospectively reviewed the records of 13 adult patients who underwent 18 different procedures. Methods to treat HALVAs include traditional bleomycin injection and CO2 laser vaporization combined with bleomycin injection between September 2009 and January 2023. Treatment results were evaluated by the grade of lumen constriction.Results: A total of five males and eight females, with an average age of 46.3 years (range, 22–66 years), were included in the study. The huge adult laryngeal vascular anomalies in our study were greater than 1633.71 mm3, and the long diameters of the bases were longer than 15 mm. Compared with the bleomycin injection‐only group, the results with the CO2 laser vaporization and bleomycin injection combined were better.Conclusions: Both bleomycin injection and CO2 laser vaporization are safe treatment methods. Their combination may produce better results for huge adult laryngeal vascular anomalies.
- Open Access
- 14 June 2024
- Published by Association for Computing Machinery (ACM)
- p. 58-62
Feature Pyramid Network and Gated Recurrent Unit-based Obstructive Events Detection from Nighttime Audio
Accurate localization of obstructive sites in the upper airway during sleep is of great importance for the guidance of OSA surgery. Nighttime audio signals, which gain the advantages of low-cost, non-invasiveness, and real-time monitoring, have been extensively applied in obstructive sites recognition. However, most of the existing research has only focused on obstructive sites classification, overlooking the events-related information (such as the start time, end time, duration, etc.), thereby diminishing the clinical applicability. In this paper, a Feature Pyramid Network (FPN) and Gated Recurrent Unit (GRU)-based framework to detect the occurrence and duration time of obstructive events is proposed. Using the FPN Backbone to extract multi-level feature representations can effectively handle large-scale changes in the duration of detection event. GRU is used to capture relationships among frequency variables over different time points. The proposed method achieved optimal event-based results with F1-score of 79% at an IoU of 0.3 and 64% at an IoU of 0.5. Experimental results have demonstrated the effectiveness of the proposed method in the field of obstructive events detection, which is expected to pave the way for more in-depth sleep-related breathing events analysis and detection.
- 14 June 2024
- Published by Association for Computing Machinery (ACM)
- p. 58-62
Open AccessFeature Pyramid Network and Gated Recurrent Unit-based Obstructive Events Detection from Nighttime Audio
Accurate localization of obstructive sites in the upper airway during sleep is of great importance for the guidance of OSA surgery. Nighttime audio signals, which gain the advantages of low-cost, non-invasiveness, and real-time monitoring, have been extensively applied in obstructive sites recognition. However, most of the existing research has only focused on obstructive sites classification, overlooking the events-related information (such as the start time, end time, duration, etc.), thereby diminishing the clinical applicability. In this paper, a Feature Pyramid Network (FPN) and Gated Recurrent Unit (GRU)-based framework to detect the occurrence and duration time of obstructive events is proposed. Using the FPN Backbone to extract multi-level feature representations can effectively handle large-scale changes in the duration of detection event. GRU is used to capture relationships among frequency variables over different time points. The proposed method achieved optimal event-based results with F1-score of 79% at an IoU of 0.3 and 64% at an IoU of 0.5. Experimental results have demonstrated the effectiveness of the proposed method in the field of obstructive events detection, which is expected to pave the way for more in-depth sleep-related breathing events analysis and detection.
- Open Access
- 9 June 2024
- Published by Wiley in World Journal of Otorhinolaryngology - Head and Neck Surgery
- Vol. 11 (2) , 276-280
Development and validity of type II sulcus vocalis in excised canine larynx
Objectives: This study aims to develop a sulcus vocalis model in the excised canine larynx and to investigate the validity of the model.Methods: Type II sulcus vocalis was created by continuous intradermal suture in six excised canine larynges. We investigated the validity of the model based on phonatory (aerodynamic and acoustic) measures, laryngeal videostroboscopy (LVS), and histological examination. The aeroacoustic parameters included phonation threshold pressure (PTP), fundamental frequency (Fo), jitter %, shimmer %, and harmonics‐to‐noise ratio (HNR).Results: In all the experimental specimens, there were significant increases in the PTP ([6.61 ± 1.66] cm H2O, p < 0.01), the Fo ([106.48 ± 49.59] Hz, p = 0.003), the jitter ([0.76 ± 0.42]%, p = 0.007), the shimmer ([6.87 ± 2.99%, p = 0.002]), while the HNR decreased ([5.71 ± 4.68] dB, p = 0.031), compared to that of the untreated canine larynges. The estabilished model simulated the histology with type Ⅱ sulcus.Conclusions: Type Ⅱ sulcus vocalis was successfully created in excised canine larynx. The aeroacoustic and LVS analysis of this model resembled the characteristics of patients with sulcus vocalis. The model could be helpful to elucidate the pathology of the phonation, and evaluate and compare the treatments for sulcus vocalis.
- 9 June 2024
- Published by Wiley in World Journal of Otorhinolaryngology - Head and Neck Surgery
- Vol. 11 (2) , 276-280
Open AccessDevelopment and validity of type II sulcus vocalis in excised canine larynx
Objectives: This study aims to develop a sulcus vocalis model in the excised canine larynx and to investigate the validity of the model.Methods: Type II sulcus vocalis was created by continuous intradermal suture in six excised canine larynges. We investigated the validity of the model based on phonatory (aerodynamic and acoustic) measures, laryngeal videostroboscopy (LVS), and histological examination. The aeroacoustic parameters included phonation threshold pressure (PTP), fundamental frequency (Fo), jitter %, shimmer %, and harmonics‐to‐noise ratio (HNR).Results: In all the experimental specimens, there were significant increases in the PTP ([6.61 ± 1.66] cm H2O, p < 0.01), the Fo ([106.48 ± 49.59] Hz, p = 0.003), the jitter ([0.76 ± 0.42]%, p = 0.007), the shimmer ([6.87 ± 2.99%, p = 0.002]), while the HNR decreased ([5.71 ± 4.68] dB, p = 0.031), compared to that of the untreated canine larynges. The estabilished model simulated the histology with type Ⅱ sulcus.Conclusions: Type Ⅱ sulcus vocalis was successfully created in excised canine larynx. The aeroacoustic and LVS analysis of this model resembled the characteristics of patients with sulcus vocalis. The model could be helpful to elucidate the pathology of the phonation, and evaluate and compare the treatments for sulcus vocalis.
- 5 January 2024
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 281 (4) , 1865-1875
Systemic bevacizumab for treatment of recurrent respiratory papillomatosis
Objectives To characterize treatment response of recurrent respiratory papillomatosis (RRP) including adult-onset RRP (AORRP) and juvenile-onset RRP (JORRP) to systemic bevacizumab (bev), and share our treatment regimen experience. Methods Patients were enrolled in bev treatment based on a pathologically confirmed diagnosis of squamous papilloma. According to lesion characteristics and medical history, systemic bev was used as preoperative adjuvant therapy, postoperative adjuvant therapy, or primary therapy. The assessment of treatment response relied on the morphological changes of lesions. Vocalization and voice-related quality of life were evaluated using the voice handicap index-30 (VHI-30) for adults and the pediatric VHI (pVHI) for children. Adverse effect was monitored through patient self-reported symptoms and regular follow-ups. Results This study included 24 patients, comprising nine AORRP and 15 JORRP cases. In AORRP, all patients (100%) exhibited various degrees of response to systemic bev, with 5 (55.56%) achieving complete response (CR). Among JORRP patients, 14 (93.33%) showed a response to systemic bev, with 8 (53.33%) achieving CR and currently being followed up. No instances of aggravation were observed during systemic bev treatment. A total of 21 patients (21/24, 87.50%) reported voice improvement, accompanied by reduced VHI-30 or pVHI scores across all aspects, including total, functional, physical, and emotional dimensions. No grade 3 or higher adverse events occurred. The most common adverse events were grade 1 gum bleeding (n = 4, 16.67%) and grade 1 proteinuria (n = 4, 16.67%). Conclusions Systemic bev can be used as a powerful therapy for both AORRP and JORRP. The findings provide a reference to the systemic bev treatment for RRP.
- 5 January 2024
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 281 (4) , 1865-1875
Systemic bevacizumab for treatment of recurrent respiratory papillomatosis
Objectives To characterize treatment response of recurrent respiratory papillomatosis (RRP) including adult-onset RRP (AORRP) and juvenile-onset RRP (JORRP) to systemic bevacizumab (bev), and share our treatment regimen experience. Methods Patients were enrolled in bev treatment based on a pathologically confirmed diagnosis of squamous papilloma. According to lesion characteristics and medical history, systemic bev was used as preoperative adjuvant therapy, postoperative adjuvant therapy, or primary therapy. The assessment of treatment response relied on the morphological changes of lesions. Vocalization and voice-related quality of life were evaluated using the voice handicap index-30 (VHI-30) for adults and the pediatric VHI (pVHI) for children. Adverse effect was monitored through patient self-reported symptoms and regular follow-ups. Results This study included 24 patients, comprising nine AORRP and 15 JORRP cases. In AORRP, all patients (100%) exhibited various degrees of response to systemic bev, with 5 (55.56%) achieving complete response (CR). Among JORRP patients, 14 (93.33%) showed a response to systemic bev, with 8 (53.33%) achieving CR and currently being followed up. No instances of aggravation were observed during systemic bev treatment. A total of 21 patients (21/24, 87.50%) reported voice improvement, accompanied by reduced VHI-30 or pVHI scores across all aspects, including total, functional, physical, and emotional dimensions. No grade 3 or higher adverse events occurred. The most common adverse events were grade 1 gum bleeding (n = 4, 16.67%) and grade 1 proteinuria (n = 4, 16.67%). Conclusions Systemic bev can be used as a powerful therapy for both AORRP and JORRP. The findings provide a reference to the systemic bev treatment for RRP.
- Open Access
- 7 July 2023
- Published by Elsevier in Journal of Voice
- Vol. 39 (6) , 1676-1682
Effect of Virtual Reality Distraction on Satisfaction and Tolerability in Patients Undergoing In-Office KTP Laser Procedure
- 7 July 2023
- Published by Elsevier in Journal of Voice
- Vol. 39 (6) , 1676-1682
Open AccessEffect of Virtual Reality Distraction on Satisfaction and Tolerability in Patients Undergoing In-Office KTP Laser Procedure